IPO registrations (S-1, F-1) · Registrants
CURIS INC
- SEC CIK
- 1108205 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2000-11-29, last 2026-08-10; 3 initial registrations, 1 amendment
- Outcome
- Final prospectus filed 2026-08-13; declared effective 2007-09-10
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 128 SPRING STREET, BUILDING C, SUITE 500, Lexington, MA 02421
- EIN
- 04-3505116
- Ticker
- CRIS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CURIS INC on the corporate pages
Offering terms
- Final price
- $1.50 per share (424B4 filed 2026-08-13)
- Shares sold
- 335,001
- Gross proceeds
- $502,501 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CRIS
- Lead underwriters
- A.G.P./Alliance Global Partners
- Syndicate
- Laidlaw & Company
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: CURIS, INC. EXACT (EIN (EXACT))
- SEC filer: CURIS INC EXACT (CIK (EXACT))
Filings 20
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-11-29 | S-1 | S-1 (registration) | CURIS INC | 0000927016-00-004209 ↗ |
| 2000-12-19 | S-1/A | S-1/A (amendment) | CURIS INC | 0000927016-00-004414 ↗ |
| 2007-09-10 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-07-003599 ↗ |
| 2008-08-18 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-08-002586 ↗ |
| 2011-01-11 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-11-000129 ↗ |
| 2013-07-22 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-13-002157 ↗ |
| 2015-05-01 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-15-001168 ↗ |
| 2015-09-02 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-15-002428 ↗ |
| 2016-12-16 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-16-006483 ↗ |
| 2018-05-17 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-18-001281 ↗ |
| 2022-04-14 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-22-000976 ↗ |
| 2024-04-12 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-24-000952 ↗ |
| 2025-01-07 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-25-000047 ↗ |
| 2025-05-19 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-25-001654 ↗ |
| 2025-08-11 | S-1 | S-1 (registration) | CURIS INC | 0001108205-25-000089 ↗ |
| 2025-08-18 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-25-002667 ↗ |
| 2026-03-20 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-26-000885 ↗ |
| 2026-08-10 | S-1 | S-1 (registration) | CURIS INC | 0001108205-26-000109 ↗ |
| 2026-08-12 | EFFECT | EFFECT (declared effective) | CURIS INC | 9999999995-26-002653 ↗ |
| 2026-08-13 | 424B4 | 424B4 (final prospectus) | CURIS INC | 0001108205-26-000116 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | S-1 | registration statement | 3,731,344 | - | Nasdaq CRIS | 2 | primary document; shares general, cover names 2 | document ↗ | ||
| 2026-08-13 | 424B4 | final prospectus | $1.50 | 335,001 | $502,501 | Nasdaq CRIS | 2 | primary document; price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| NOEL MARK | Officer | Vice-President; VP, Tech Management | 16 | 2006–2013 | |
| BAYH SUSAN B | Director | 10 | 2006–2013 | ||
| DAVIE JOSEPH M | Director | 3 | 2006–2007 | ||
| GRAY MICHAEL | Officer | CBO and CFO; CFO; Chief Financial Officer; COO and CFO | 19 | 2006–2015 | |
| GREENACRE MARTYN D | Director | 28 | 2006–2026 | ||
| KAITIN KENNETH I | Director | 27 | 2006–2026 | ||
| MCNAB JAMES R | Director | 30 | 2006–2017 | ||
| MELTON DOUGLAS | Director | 3 | 2006 | ||
| PASSERI DANIEL R | Director; Director,Officer; Officer | CEO; CEO and Director | 28 | 2006–2016 | |
| POTTHOFF MARY ELIZABETH | Officer | VP and General Counsel | 1 | 2006 | |
| TOBIN JAMES R | Director | 14 | 2006–2015 | ||
| Qian Changgeng | Officer | VP, Research & Preclinical Dev | 8 | 2007–2011 | |
| ALDRICH RICHARD | TenPercentOwner | 3 | 2007–2008 | ||
| Kolchinsky Peter | TenPercentOwner | 3 | 2007–2008 | ||
| RA Capital Biotech Fund II, L.P. | TenPercentOwner | 3 | 2007–2008 | ||
| RA Capital Biotech Fund LP | TenPercentOwner | 3 | 2007–2008 | ||
| RA CAPITAL MANAGEMENT, LLC | TenPercentOwner | 3 | 2007–2008 | ||
| CARTER STEPHEN | Director | 3 | 2007–2008 | ||
| DAVIE JOSEPH MD PHD | Director | 4 | 2008–2011 | ||
| BIOTECHNOLOGY VALUE FUND II LP | Other; TenPercentOwnerOther | 2 | 2009 | ||
| BIOTECHNOLOGY VALUE FUND L P | Other; TenPercentOwnerOther | 2 | 2009 | ||
| BVF INC/IL | TenPercentOwnerOther | 2 | 2009 | ||
| BVF INVESTMENTS LLC | Other; TenPercentOwnerOther | 2 | 2009 | ||
| BVF PARTNERS L P/IL | TenPercentOwnerOther | 2 | 2009 | ||
| Keegan Mitchell | Officer | Vice-President | 5 | 2009–2011 | |
| Rubin Marc | Director | 24 | 2010–2026 | ||
| Martell Robert | Director; Officer | Head of Research & Development | 16 | 2011–2023 | |
| Voi Maurizio | Officer | Chief Medical Officer | 4 | 2011–2013 | |
| Fattaey Ali Ph.D. | Director,Officer; Officer | President & CEO; President & COO | 13 | 2013–2018 | |
| Pienta Kenneth | Director | 8 | 2013–2017 | ||
| Viner Jaye | Officer | Chief Medical Officer | 6 | 2013–2015 | |
| Aurigene Discovery Technologies Ltd | TenPercentOwner | 2 | 2015–2016 | ||
| DR REDDYS LABORATORIES LTD | TenPercentOwner | 2 | 2015–2016 | ||
| Mohindru Mani | Officer | Chief Strategy Officer; Sr. VP, Corp. Strategy & IR | 4 | 2016–2017 | |
| Tuck David | Officer | Chief Medical Officer; Sr. Vice-President | 5 | 2016–2018 | |
| Dentzer James E | Director,Officer; Officer | Chief Financial Officer; COO & CFO; President & CEO | 20 | 2016–2026 | |
| Dr. Reddy's Holdings Ltd | TenPercentOwner | 1 | 2016 | ||
| Kunkel Lori Anne | Director | 9 | 2016–2022 | ||
| Steinkrauss William | Officer; OfficerOther | Chief Financial Officer; VP, Finance & Treasurer | 5 | 2019–2022 | |
| Hohneker John | Director | 8 | 2021–2026 | ||
| Duvall Diantha | Officer | CFO | 8 | 2022–2026 | |
| Borgman Anne Elizabeth | Director | 7 | 2022–2026 | ||
| Zung Jonathan B. | Officer | CDO | 8 | 2023–2026 | |
| Hamdy Ahmed MD | Officer | CMO | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | CURIS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | CURIS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- ACCELERON PHARMA INC MA
- bluebird bio, Inc. MA
- Altus Pharmaceuticals Inc. MA
- BioVex Group, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health